Americas

Takeda’s Dengue Vaccine Candidate Provides Continued Protection Against Dengue Fever Through 4.5 Years of Clinical Trials

In long-term exploratory analysis, TAK-003 prevented 84% of hospitalizations and 61% of symptomatic dengue illness overall, with no identified important safety risks.